105 results about "Tretinoina" patented technology

An improved method and preparation for the treatment of acne and hirsutism comprises topically applying an effective amount of a saw palmetto berry extract, in combination with two classes of low irritability penetrating agents that enhance penetration of the extract into hair follicles and sebaceous glands. The low irritability penetration agents are selected from the group (A) comedolytics consisting of adapalene, tretinoin, tretinoin gel microsponges, retinaldehyde, retinol, and tazarotene, and (B) keratinolytics consisting of the beta hydroxy acid, salicylic acid, and the alpha hydroxy acid, glycolic acid. Polyolprepolymer-2 may be incorporated into the preparation as well.

The invention discloses an all-trans retinoic acid-camptothecin anticancer drug conjugate as well as a preparation method and application thereof. The structural formula of the all-trans retinoic acid-camptothecin anticancer drug conjugate is shown in a formula (I), (II), (III), (IV), (V) or (VI). The all-trans retinoic acid-camptothecin anticancer drug conjugate has good solubility in Tween, polyoxyethylene castor oil, a Poly(ethylene adipate)-polylactic acid copolymer and a Poly(ethylene adipate)-poly (lactic acid-glycollic acid) copolymer, can be self assembled into nanometer grains in water, can be directly injected or taken orally or processed into other dosage forms. According to the all-trans retinoic acid-camptothecin anticancer drug conjugate disclosed by the invention, as all-trans retinoic acid and SN-38 or camptothecin take synergistic effect, compared with a conjugate only containing one of irinotecan, SN-38 and all-trans retinoic acid, the all-trans retinoic acid-camptothecin anticancer drug conjugate has good tumor suppression effect.

A composite lipid for treating and preventing pigmentation and photosenile dermatopathy is prepared from tretinoin, licoflavone, lecithin and surfactant through including the tretinoin and licoflavone in lecithin.

The invention discloses a medium composition for inducing mesenchymal stem cells into insulin-secreting cells. The medium composition comprises a medium A, a medium B and a medium C. The medium A comprises the following solutes: a fetal calf serum with a concentration of 4.75 to 5.25 ml/L and activin A with a concentration of 4.75 to 5.25ng/mL. The medium B comprises the following solutes: retinoic acid with a concentration of 0.95 * 10<-5> to 1.05 * 10<-5> mol/L, EGF with a concentration of 19 to 21ng/ml, bFGF with a concentration of 19 to 21ng/ml, glutamine with a concentration of 1.9 to 2.1 mmol/L, 0.95 to 1.05% of non-essential amino acids and 1.9 to 2.1% of B27. The medium C comprises the following solutes: a fetal bovine serum with a concentration of 4.5 to 5.5 ml/L, exendin-4 with a concentration of 19 to 21 ng/ml, activin A with a concentration of 9.5 to 10.5 ng/ml, nicotinamide with a concentration of 9.5 to 10.5 mmol/L, 1.9 to 2.1% of B27 and 0.95 to 1.05% of N2. An induction culture method provided by the invention is applicable to a variety of tissue-derived mesenchymal stem cells and has the advantages of no introduction of viruses, easy operation and high efficiency.

The invention discloses probiotics and application thereof in secondary osteoporosis, and belongs to the technical field of microorganisms. The lactobacillus plantarum HFY15 is lactic acid bacteria (LAB) with the preservation number of CGMCC No. 16648, and the Lactobacillus plantarum HFY15 is separated and identified from natural yak yoghourt. A rat secondary osteoporosis (OP) model is establishedby using retinoic acid, and prevention effect of the ahfy15 on the OP is researched; the results show that the supplement of the HFY15 increases the expression of osteogenic marker genes, inhibits the expression of osteoclast genes, and stimulates the formation of bones; and a research result provides a new effective strategy for prevention and treatment of OP.

The invention relates to a medicine composition for treating osteoporosis, in particular to the medicine composition of rhizoma drynariae and radix salviae miltiorrhizae, and medicinal application thereof. The weight ratio of the rhizoma drynariae to the radix salviae miltiorrhizae is 1:0.2-10. Main active ingredients in the extract of the composition are a flavonoid compound from rhizoma drynariae, a diterpenoid tanshinone compound from radix salviae miltiorrhizae and a salvianolic acid compound, wherein contents of the three active ingredients, namely total flavonoids from the rhizoma drynariae, tanshinone and salvianolic acids, are not lower than 40 percent of total weight of the extract. The extract of the composition can effectively avoid reduction of rat bone density caused by retinoic acid, has the remarkable effect of promoting blood circulation by removing blood stasis, and can be used for preparing the medicine for preventing and treating the osteoporosis. The traditional Chinese medicine composition has the advantages of simple formulation, high content of effective ingredients, controllable quality, safety and efficiency.

The present invention discloses a compound gel preparation-compound tretinoin gel preparation for curing acnes. It is made up by using carbomer, glycerine, propylene alcohol, Tween, triethanolamine, clindamycin phosphate, tretinoin, EDTA and distilled water as raw material through a certain preparation process. Said invention also provides the concrete steps of its preparation method.

The invention belongs to the technical field of medicine and discloses bexarotene hydroximic acid as well as a preparation method and application thereof. The formation of the compound is as shown in the picture and the objective compound is prepared mainly by taking 1,1,4,4,6- pentamethyl-1,2,3,4-tetrahydronaphthalene as the initial material through the steps of Friedel-Crafts acylation, Wittig reaction and condensation reaction. The method is simple in operation, convenient in post-processing and high in yield. The objective compound has good inhibitory action on various cancer cells by the multiple action mechanisms of bonding the retinoic acid X receptors and restraining the histone deacetyltransferases, and the anti-cancer activity of the bexarotene hydroximic acid is obviously better than that of bexarotene. Therefore, the bexarotene hydroximic acid can be applied to treatment of cancers.

The present invention discloses compounds for the treatment of cancer and its application. These compounds comprises one of the following compound: Ammonium pyrrolidinedithiocarbamate Bay 11-7085 BIO Brefeldin A (+)-Butaclamol Calcimycin Calmidazoliur chloride Chelerythrine chloride CK2 Inhibitor 2 CGP-74514A hydrochloride CGS-12066A meleate Dequalinium dichloride Dihydroouabain Diphenyleneiodonium chloride Emetine dihydrochloride hydrate GR 127935 hydrochloride Nifedipine 6-Nitroso-1,2-benzopyrone Palmitoyl-DL-Carnitine chloride Parthenolide PD 169316 1,10-Phenanthroline monohydrate 4-Phenyl-3-furoxancarbonitrile Prazosin hydrochloride Protoporphyrin IX disodium Quinacrine dihydrochloride Quabain Retinoic acid p-hydroxyanilide Rottlerin Sanguinarine chloride Tetraethylthium disulfide and SU 9516. The invention also provides new uses of these compounds, compounds such as for the preparation of the treatment of cancer, inhibit cancer cell, cancer stem cell growth and provides a new pharmaceutical composition for treating cancers

The invention discloses a compound used for treating acne and an application thereof. The compound has obvious effect for treating acne, and can alleviate side effect of retinoic acid by combining with retinoic acid.

The invention features all-trans retinoic acid (ATRA)-related compounds capable of associating with Pin1 and methods of treating a proliferative disorder characterized by elevated Pin1 marker levels, Pin1 degradation, and/or reduced Pin1 Ser71 phosphorylation in a subject by administering an ATRA-related compound. The invention also features methods of treating proliferative disorders, autoimmune diseases, and addiction conditions (e.g., diseases, disorders, and conditions characterized by elevated Pin1 marker levels) by administering an ATRA-related compound in combination with another therapeutic compound.

The invention relates to a method for preparing a retinoic hydroxyapatite bionic compound and the bionic compound. By virtue of the method for preparing the retinoic hydroxyapatite bionic compound and the retinoic hydroxyapatite bionic compound prepared by utilizing the method, a bone is formed by utilizing the bionic compound in the clinical application, the cost is low, the effect of bone formation is good, and ectopic bone formation, postoperative swelling and other complications can be effectively avoided. The technical scheme adopted by the invention is as follows: the preparation method comprises the following steps: a, preparing a core of a bionic layer; b, coating the surface of the core of the bionic layer with a functional layer; c, coating the surface of the product obtained in the step with one more functional layer. The bionic compound is mainly applied to the technical field of medical appliances.

The invention features all-trans retinoic acid (ATRA)-related compounds capable of associating with Pin1 and methods of identifying the same. The invention also provides methods of treating a condition selected from the group consisting of a proliferative disorder, an autoimmune disease, and an addiction condition characterized by elevated Pin1 marker levels, Pin1 degradation, and/or reduced Pin1 Ser71 phosphorylation in a subject by administering a retinoic acid compound. Additionally, the invention features methods of treating proliferative disorders, autoimmune diseases, and addiction conditions (e.g., diseases, disorders, and conditions characterized by elevated Pin1 marker levels) by administering a retinoic acid compound in combination with another therapeutic compound. The invention also features a co-crystal including Pin1 and a retinoic acid compound. Finally, the invention also provides methods of developing and identifying enhanced Pin1-targeted ATRA-related compounds based on the newly defined unique binding pockets in the Pin1 active site revealed from the co-crystal structure, structure-activity relationship, and structural modeling.

The invention relates to application of amphipathic pegylated retinoic acid and a self-assembly micelle thereof in drug delivery. An amphipathic prodrug block takes polyethylene glycol as a hydrophilic end and is bonded with hydrophobic retinoic acid through an ester bond, so that an AB type amphipathic prodrug block is obtained. The polymer has effects of potential treatment for leukemia and prolonging the half life of drug, has a higher drug loading rate, and effectively increases gastrointestinal mucosa permeability so as to increase the oral bioavailability. The pegylated prodrug is self-assembled to form the micelle in an aqueous medium, and the micelle can be used as a storage cavern of the indissolvable drug retinoic acid to slowly release retinoic acid. The micelle is good in safety, can be used for oral administration, and has a great market application prospect.

The invention discloses emodin as an inhibitor of activated molecules p-Akt and p-mTOR of a PI3K/Akt/mTOR signal transduction pathway and application thereof, wherein the emodin is a purely natural anthraquinone monomer compound extracted from rhubarb as a Chinese traditional medicine and has multiple biologic activities such as anti-microbes, anti-inflammation, antioxidation, immune regulation, liver protection and the like. The invention finds that after acute leukemia multidrug-resistance cells HL-60/ADR, acute promyelocytic leukemia retinoic acid drug-resistant cells MR2 as well as corresponding sensitive cells NB4 and acute leukemia primary cells are acted by the rhubarb, key signal activated molecules of the PI3K/Akt/mTOR signal transduction pathway, particularly p-Akt and p-mTOR, are inhabited with specificity; in vivo researches verify that after the emodin is dosed, all the key activated molecules p-Akt, p-p65 and p-mTOR of the PI3K/Akt/mTOR signal pathway in acute leukemia nude mouse transplanted tumor tissue protein are expressed and downwards regulated, which indicates that the emodin can be used as a novel targeting inhibitor for PI3K/Akt/mTOR signal transduction activated molecules, particularly p-Akt and p-mTOR, and is applied to treating malignant tumors of a blood system.

Belonging to the field of biomedicine, the invention relates to a method for paeoniflorin to induce umbilical cord mesenchymal stem cells to differentiate into endothelial cells and application thereof. In the invention, the paeoniflorin has a structure as shown in formula (I). The induction differentiation steps of the method comprise: inducing the umbilical cord mesenchymal stem cells respectively in a beta-mercaptoethanol medium with a concentration of 1-100micromoles/L and a retinoic acid 5%DMEM medium with a concentration of 1-100micromoles/L for 24h, then shifting the cells into a paeoniflorin-containing endothelial cell conditioned medium, half of the solution is changed every two days. And after 10-14d of induction, umbilical cord mesenchymal stem cell derived endothelial cells can be obtained. In the invention, the application of the paeoniflorin and the method can promote differentiation of the umbilical cord mesenchymal stem cells, improve the differentiation efficiency, and can be used in cell transplantation treatment of ischemic vascular diseases. The obtained endothelial cells can be further prepared into cell preparations to be used for ischemic vascular disease treatment, and seed cell application of vascular tissue engineering.

The invention relates to an autologous adipose cell cryopreservation solution and a cryopreservation method of substances such as adipose tissue-derived stromal cells. Every 100 mL of the autologous adipose cell cryopreservation solution comprises the following content components: 20 to 38 mL of mesenchymal stem cell culture supernatant, 3 to 5 g of polyvinylpyrrolidone, 3 to 5 mL of glycerinum, 1.5 to 2 g of hydroxyapatite nanoparticles, 1.5 to 2 g of trehalose, 0.5 to 1 g of polyvinyl alcohol, 0.01 to 0.1 g of human serum albumin, 0.05 to 0.3 g of adenosine triphosphate, 0.5 to 1.5 mg of all-trans retinoic acid, 0.3 to 0.8 g of vitamin C, 0.2 to 0.6 g of vitamin E and 0.2 to 0.6 g of lipoic acid. Compared with the prior art, ice crystal formation can be effectively reduced, and cell damage caused by uneven temperature conduction and sharp ice crystal formation is prevented.

The application of the invention discloses an application of all-trans retinoic acid to mesenchymal stem cell polarization regulation. The application of all-trans retinoic acid to mesenchymal stem cell polarization regulation specially comprises the application of the all-trans retinoic acid to restraining of polarization of mesenchymal stem cells to osteoblasts and adipocyte. The application research confirms that the all-trans retinoic acid can restrain the polarization of mesenchymal stem cells to the osteoblast and the polarization. The application provides a new function application of the all-trans retinoic acid based on the application, the polarization regulation of the mesenchymal stem cells is researched, and polarization potential of the mesenchymal stem cells is adjusted and controlled directionally. The invention provides a new tool and an adjusting means.

The invention belongs to the technical field of biology and particularly relates to a pharmaceutical application of all-trans-retinoic acid.By extensive and deep researches, the new application of the all-trans-retinoic acid to preparation of medicines capable of inducing formation of tissue resident memory T cells is discovered for the first time and lays a foundation for development of brand-new mucosal immunization strategies taking the ATRA (all-trans-retinoic acid) as an adjuvant.

The invention relates to the field of pharmacy, and in particular relates to a preparation process of an all-trans retinoic acid liposome preparation and a composite liposome preparation. According tothe invention, the all-trans retinoic acid liposome and the composite liposome thereof are prepared by using an active drug loading method; and the lipidosome is obtained by the following steps: (1)preparing a pH gradient blank lipidosome; (2) dissolving all-trans retinoic acid and a co-loaded drug into an organic solvent capable of being mixed and dissolved with water, and dropwise adding the mixture into the blank liposome, and (3) performing incubating at a certain temperature, so as to enable the all-trans retinoic acid and the co-loaded drug to actively enter the liposome, thereby obtaining the all-trans retinoic acid liposome and the composite liposome preparation thereof. The method has the characteristics of high encapsulation efficiency, high drug loading capacity, good stability, high safety and the like.

The invention discloses an application of a polypyrimidine sequence binding protein silencing agent combined with retinoic acid and purinine amine in preparation of a medicine for repairing spinal cord injury, and belongs to the technical field of biological medicine. The polypyrimidine sequence binding protein (PTB) is silenced in vitro through a virus, and meanwhile, micromolecule retinoic acid (RA) and purinol amine (PMA) which are related to motor neuron differentiation are jointly added, so that mouse spinal cord reactive astrocytes are successfully reprogrammed into motor neuron; and help is provided for further in-vivo research on the effect of a PTB combined micromolecule reprogramming strategy in spinal cord injury post-repair, so that better spinal cord injury repair and function reconstruction effects are realized.

The invention provides a medicament for treating femoral head necrosis. The medicament is prepared from the following traditional Chinese medicinal materials in parts by weight: 40-50 parts of pseudo-ginseng, 75-90 parts of suberect spatholobus stem, 75-90 parts of radix achyranthis bidentatae, 75-90 parts of medlar, 75-90 parts of teasel root, 75-90 parts of rhizoma drynariae (sand heated), 75-90 parts of salviae miltiorrhizae, 75-90 parts of Chinese angelica, 75-90 parts of ligusticum wallichii, 75-90 parts of cortex acanthopanacis, 115-130 parts of prepared rehmannia root, 115-130 parts of codonopsis pilosula, 75-90 parts of rhizoma atractylodis macrocephalae, 115-130 parts of prepared frankincense, 115-130 parts of prepared myrrh, 115-130 parts of corydalis tuber, 20-25 parts of rheum officinale, 75-90 parts of radix curcumae and 75-90 parts of costusroot. The medicament can be used for improving the testosterone of a rat caused by hydrocortisone, reducing T3 and T4, increasing the relative volume and average bone trabecula width, improving resistance of a kidney-deficiency mouse, improving relative bone volume reduction and average bone trabecula width reduction caused by tretinoin, improving contents of bone calcium and phosphor, improving microcirculation disturbance, diminishing swelling and relieving pain and improving immunity, and has a good curative effect in the aspect of treating femoral head necrosis.

Provided is a pharmaceutical composition for the treatment of liver cancer, including a layered metal hydroxide-retinoic acid (LMH-RA) hybrid as a novel drug delivery system which shows few side effects of retinoic acid, good drug stability, sustained drug release, and improved drug delivery efficiency.

The invention relates to application of a retinoic acid-induced gene I in cancer treatment, and belongs to the technical field of biological medicines. The invention discloses an application of a retinoic acid induced gene I in preparation of a medicine for treating tumors. Application in preparation of T cells for tumor treatment; application in preparation of drugs for improving immunity; the application relates to inhibition of retinoic acid induced gene I expression and improvement of a CD8 + T cell specific killing function. The invention discloses an application of RIG-I in cancer treatment as a target spot of immunotherapy. Knockout of RIG-I can promote survival of CD8 + T cells, enhance the anti-tumor immune function of the T cells and improve the inhibitory immune tumor microenvironment, so that tumor growth is obviously slow. The discovery of the target spot provides a new thought for clinical application of CART or TCRT in tumor immunotherapy.